spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Axon Regeneration 

 HSMN NewsFeed - 14 Sep 2011
AxoGen Avance(R) Nerve Graft Clinical Study Results Presented at the American Society of Surgery of the Hand
Devices Neurosurgery Regenerative Medicine
 HSMN NewsFeed - 18 Sep 2008
The European Commission Grants Orphan Drug Designation to Alseres Pharmaceuticals' Spinal Cord Injury Treatment, Cethrin(R)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 17 Apr 2008
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Biopharmaceuticals Diagnostics Neurology
 HSMN NewsFeed - 4 Dec 2007
AxoGen Receives $12.1 Million in Venture Capital Funding
Devices Venture Capital
 HSMN NewsFeed - 24 Sep 2007
Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Jun 2007
Alseres Pharmaceuticals Announces FDA Clearance to Increase Dose Level in Cethrin(R) Phase I/IIa Clinical Trial for Acute Spinal Cord Injury at U.S. Sites
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 8 Jun 2007
Boston Life Sciences, Inc. Changes Name to Alseres Pharmaceuticals, Inc.
Biopharmaceuticals
 HSMN NewsFeed - 29 May 2007
Boston Life Sciences Names Scientific and Clinical Advisors for Nerve Repair Program
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Apr 2007
Boston Life Sciences Appoints Frank Bobe as Executive Vice President and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Mar 2007
Dr. Robert Langer Named as Chairman of Boston Life Sciences, Inc. Newly Formed Science and Technology Committee of the Board of Directors
Devices Personnel
 HSMN NewsFeed - 4 Jan 2007
Boston Life Sciences Acquires Rights to Develop and Commercialize Promising Phase II Spinal Cord Injury Drug, Cethrin(R), in Exclusive Worldwide License
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 11 May 2006
Boston Life Sciences, Inc. Solidifies Comprehensive Axon Regeneration Position with Children's Hospital Boston
Biopharmaceuticals Neurology Regenerative Medicine
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
Axon Regeneration
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.